Citation

McDougle CJ, Stigler KA, Erickson CA, Posey DJ. J. Clin. Psychiatry 2008; 69(Suppl 4): 15-20.

Affiliation

Department of Psychiatry, Indiana University School of Medicine, Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202-4800, USA. cmcdougl@iupui.edu

Copyright

(Copyright © 2008, Physicians Postgraduate Press)

DOI

unavailable

PMID

18533764

Abstract

Atypical antipsychotics are emerging as the first-line pharmacologic treatment for irritability (i.e., aggression, self-injurious behavior, and severe tantrums) in children and adolescents with autistic and other pervasive developmental disorders. Results from placebo-controlled and open-label studies of clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole in this subject population are reviewed. Additional placebo-controlled trials and studies of longer-term safety and tolerability are needed.

Language: en